The Food and Drug Administration’s (FDA) new mobile app, MyStudies, marks a significant milestone for the collection of real-world data, Iqvia Senior Vice President and General Manager John Doyle tells Outsourcing-Pharma.com.
“On the patient-centricity initiative, it amplifies the patient voice, providing them with the ability to contribute patient-generated health data from their own wearable devices and medical apps,” Doyle said.
According to the report, the FDA and Kaiser Permanente partnered on a study to assess the app’s performance. The app’s source code and documentation were later released, which offers researchers customization capabilities.
“I believe this tool will serve as a gateway to development of next-generation digital tools for collecting RWD and facilitating ‘translation’ to RWE,” Doyle said.